For $200m Astrazeneca buys Neogene, and Alaunos’s long-suffering investors can just look on.
Daiichi and Astrazeneca want to extend Enhertu’s reach. But it’s hard to know whether the tests to identify the right patients actually work.
After a bruising few months for GSK, 17 global drug makers now have a higher market cap than the UK company.
Brukinsa’s head-to-head victory over Imbruvica is confirmed, and the Beigene BTK inhibitor looks better than Calquence too.
Iptacopan looks as good as Empaveli in PNH, with the added bonus of being oral.
As all eyes turn to Astra’s camizestrant, a sneak peek at Arvinas’s data suggests that ARV-471 might not be competitive.
Astra’s stealthy move into cell therapy has yielded a truly novel cancer target, and the company could be in clinical trials soon.